Bernd Schultes, Susanne Emmerich, Andreas D Kistler, Badreddine Mecheri, Oliver Schnell, Gottfried Rudofsky
J Diabetes Sci Technol. 2021;19322968211054520.
Qualitative albuminuria measurement using albumin-creatinine ratio (ACR) is recommended for the diagnosis of diabetic kidney disease (DKD). ACR can be measured in specialized laboratories or using ACR point-of-care testing (POCT). In this observational study, the authors evaluated the effect of ACR POCT utilisation on the DKD diagnosis and treatment for glycaemic control and blood pressure.
The study found that out of the 717 participants with diabetes, 39.1% had a confirmed or suspected DKD diagnosis. Of these, 8.6% were newly diagnosed with DKD and 9.9% were suspected of having DKD based on the ACR POCT values. Additionally, 100% of the physicians indicated that they used ACR POCT to examine patients with diabetes (with or without hypertension) and considered ACR POCT to be very important for patients with diabetes.
The authors conclude that the implementation of ACR POCT may positively affect DKD diagnosis and subsequently allow better management of patients with diabetes.
The full publication can be accessed here.
© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmentenAccess Now
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseenAccess Now